On Monday, June 15, 2020, the U.S. Food and Drug Administration removed the Emergency Authorization Use (EAU) of two malaria drugs to treat COVID-19, saying that they are “unlikely to be effective.”
Both hydroxychloroquine (brand name Plaquenil) and chloroquine were heavily promoted by President Trump after a handful of small, poorly controlled studies showed that they could work in treating the disease.
The FDA reported that further studies had shown that the two drugs were unlikely to be effective in stopping the virus, and that current national treatment guidelines do not recommend using them outside of clinical trials.
Hydroxychloroquine is a low-risk ototoxic drug. Please refer to this feature article for more information.
Related Posts
Havana Syndrome Sparks Debate Among Experts
Audio-vestibular symptoms are gaining national attention and sparking debate amongst professionals and the public. A CBS 60 Minute report on Sunday, March 31, revisited Havana…
ADHD in Children in the United States
Audiologists sometimes see patients who also present with a diagnosis of attention-deficit/hyperactivity disorder (ADHD). Reuben and Elgaddal (2024) reported the percentage of children in the…
Remote Diagnostic Hearing Assessment in School-Entry-Aged Children
Even before the COVID-19 pandemic, telehealth and remote audiology visits were increasing in frequency and popularity. D’Onofrio and Zeng (2021) reported that telemedicine was adapted…